260 related articles for article (PubMed ID: 31011982)
21. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
23. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
24. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial.
Mokdad AA; Zhu H; Beg MS; Arriaga Y; Dowell JE; Singal AG; Yopp AC
Target Oncol; 2019 Oct; 14(5):541-550. PubMed ID: 31429027
[TBL] [Abstract][Full Text] [Related]
27. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Feng YM; Feng CW; Lu CL; Lee MY; Chen CY; Chen SC
Jpn J Clin Oncol; 2015 Apr; 45(4):336-42. PubMed ID: 25646358
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Kaplan DE; Mehta R; D'Addeo K; Valderrama A; Taddei TH;
Medicine (Baltimore); 2018 Jan; 97(4):e9757. PubMed ID: 29369224
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
[TBL] [Abstract][Full Text] [Related]
30. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.
Sacco R; Granito A; Bargellini I; Zolfino T; Saitta C; Marzi L; Tapete G; Bresci G; Marinelli S; Tovoli F; Attardo S; Rossi M; Urbani L; Marchi S; Buccianti P; Cabibbo G
Future Oncol; 2018 Dec; 14(29):3049-3058. PubMed ID: 30091371
[TBL] [Abstract][Full Text] [Related]
32. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy.
Cheng Z; Wei-Qi J; Jin D
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188382. PubMed ID: 32522600
[TBL] [Abstract][Full Text] [Related]
33. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
34. Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
Mallick R; Cai J; Wogen J
Curr Med Res Opin; 2013 Dec; 29(12):1701-8. PubMed ID: 24010684
[TBL] [Abstract][Full Text] [Related]
35. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
36. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
Marasco G; Colecchia A; Bacchi Reggiani ML; Celsa C; Farinati F; Giannini EG; Benevento F; Rapaccini GL; Caturelli E; Di Marco M; Biasini E; Marra F; Morisco F; Foschi FG; Zoli M; Gasbarrini A; Baroni GS; Masotto A; Sacco R; Raimondo G; Azzaroli F; Mega A; Vidili G; Brunetto MR; Nardone G; Dajti E; Ravaioli F; Avanzato F; Festi D; Trevisani F;
Dig Liver Dis; 2021 Aug; 53(8):1011-1019. PubMed ID: 33353858
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Shlomai A; Leshno M; Goldstein DA
PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
